Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives

被引：31

作者：

Natsuaki, Masahiro ^{[1
]}

Sonoda, Shinjo ^{[1
]}

Yoshioka, Goro ^{[1
]}

Hongo, Hiroshi ^{[1
]}

Kaneko, Tetsuya ^{[1
]}

Kashiyama, Kuninobu ^{[1
]}

Yokoi, Kensuke ^{[1
]}

Hikichi, Yutaka ^{[2
]}

Node, Koichi ^{[1
]}

机构：

[1] Saga Univ Hosp, Dept Cardiovasc Med, 5-1-1 Nabeshima, Saga 8498501, Japan

[2] Saga Med Ctr, Cardiovasc Ctr, Koseikan, Saga, Japan

来源：

CARDIOVASCULAR INTERVENTION AND THERAPEUTICS | 2022年 / 37卷 / 02期

关键词：

Antiplatelet therapy; Antithrombotic therapy; Percutaneous coronary intervention; ELUTING STENT IMPLANTATION; ARTERY-DISEASE; CARDIOVASCULAR EVENTS; ATRIAL-FIBRILLATION; OPTIMAL DURATION; VASCULAR EVENTS; FOCUSED UPDATE; DOUBLE-BLIND; CLOPIDOGREL; ASPIRIN;

D O I：

10.1007/s12928-022-00847-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Antiplatelet therapy after percutaneous coronary intervention (PCI) has been changing in parallel with the development of drug-eluting stents (DES) and antiplatelet agents. The recommendation of dual antiplatelet therapy duration is getting shorter due to the decreased risk of stent thrombosis in new-generation DES, the use of a P2Y(12) inhibitor as a monotherapy, and the increasing prevalence of high bleeding risk patients. Antithrombotic therapy after PCI has also changed due to the introduction of direct oral anticoagulants. Aspirin-free P2Y(12) inhibitor monotherapy is now being evaluated in several prospective studies as a novel strategy of antiplatelet therapy after PCI. This review shows a current status and provides future perspectives for the antiplatelet therapy after PCI.

引用

页码：255 / 263

页数：9

共 50 条

[11] Oral antiplatelet therapy and percutaneous coronary intervention
Yan, BPY
Clark, DJ
Ajani, AE
EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (01) : 3 - 12
[12] Oral antiplatelet therapy in the elderly undergoing percutaneous coronary intervention: an umbrella review
Biondi-Zoccai, Giuseppe
Antonazzo, Barbara
Giordano, Arturo
Versaci, Francesco
Frati, Giacomo
Ronzoni, Stefano
Nudi, Alessandro
Nudi, Francesco
JOURNAL OF THORACIC DISEASE, 2020, 12 (04) : 1656 - 1664
[13] Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome
Deharo, Pierre
Cuisset, Thomas
TRENDS IN CARDIOVASCULAR MEDICINE, 2020, 30 (04) : 198 - 202
[14] Antiplatelet therapy in percutaneous coronary intervention
Bode, Christoph
Huber, Kurt
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2008, 10 (0A) : A13 - A20
[15] Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS Redefining the optimal duration of treatment
Staehli, B. E.
Landmesser, U.
HERZ, 2018, 43 (01) : 11 - 19
[16] The safety and efficacy of oral anticoagulants with dual versus single antiplatelet therapy in patients after percutaneous coronary intervention A meta-analysis
Chen, Jie
Wang, Li-Yu
Deng, Chao
Jiang, Xing-Hua
Chen, Tu-Gang
MEDICINE, 2017, 96 (37)
[17] Antiplatelet therapy after coronary intervention in Asia and Japan The Asian perspective of antiplatelet intervention
Goto, S.
Toda, E.
HAMOSTASEOLOGIE, 2009, 29 (04): : 321 - 325
[18] Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: Balancing efficacy and bleeding risk
Spinler, Sarah A.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (15) : S7 - S17
[19] Antiplatelet therapy in percutaneous coronary intervention: latest evidence from randomized controlled trials
Galli, Mattia
Angiolillo, Dominick J.
CURRENT OPINION IN CARDIOLOGY, 2021, 36 (04) : 390 - 396
[20] Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention
Bagai, Akshay
Bhatt, Deepak L.
Eikelboom, John W.
Mancini, G. B. John
Cohen, Eric A.
Vijayaraghavan, Ram
Cheema, Asim N.
Udell, Jacob A.
Niznick, Joel
Tanguay, Jean-Francois
Verma, Subodh
Mehta, Shamir R.
CIRCULATION, 2016, 133 (21) : 2094 - 2098

← 1 2 3 4 5 →